Physician profile
Ning Sun
NPI 1124022900
$3,526.60
in general payments reported to CMS, 2019-2025
28 companies · $125 in 2025
The $125 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $720 · 2020: $405 · 2021: $538 · 2022: $841 · 2023: $650 · 2024: $247 · 2025: $125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,022.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,022.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $648.50 | 2021-2024 | Ubrelvy, Qulipta |
| Teva Pharmaceuticals USA, INC. | $625.39 | 2019-2023 | Ajovy |
| Novartis Pharmaceuticals Corporation | $338.99 | 2021-2024 | |
| Acorda Therapeutics, INC | $328.98 | 2019-2023 | Inbrija, Ampyra |
| Genzyme Corporation | $204.88 | 2022-2023 | |
| Emd Serono, INC. | $166.33 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $150.92 | 2020-2021 | |
| Neurocrine Biosciences, INC. | $125.00 | 2025 | |
| Janssen Pharmaceuticals, INC | $100.24 | 2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $93.36 | 2022 | |
| Biogen, INC. | $86.65 | 2022-2023 | Vumerity, Avonex, Plegridy |
| Biohaven Pharmaceuticals, INC. | $82.37 | 2021 | |
| Endo Pharmaceuticals INC. | $66.68 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $59.11 | 2021-2022 | |
| Lilly USA, LLC | $55.16 | 2019-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $54.55 | 2023-2024 | |
| Genentech USA, INC. | $50.29 | 2021-2023 | Ocrevus, Enspryng |
| Allergan, INC. | $47.80 | 2020 | |
| Adlon Therapeutics L.P. | $39.62 | 2019 | |
| Lundbeck LLC | $39.19 | 2023 | Vyepti |
| Assertio Therapeutics, INC. | $30.69 | 2020 | |
| Abbott Laboratories | $27.57 | 2023 | Infinity |
| Supernus Pharmaceuticals, INC. | $24.73 | 2019 | |
| Amneal Pharmaceuticals LLC | $21.25 | 2019 | |
| Shire North American Group INC | $20.16 | 2019 | |
| Collegium Pharmaceutical, INC. | $14.10 | 2022 | |
| Jazz Pharmaceuticals INC. | $12.49 | 2021 | |
| Alexion Pharmaceuticals, INC. | $11.60 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ning Sun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.